Schizophrenic Patients’ Subjective Reasons for Compliance and Noncompliance with Neuroleptic Treatment

W. Löffler; R. Kilian; M. Toumi; M. C. Angermeyer

doi:10.1055/s-2003-39985

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2003; 36(3): 105-112
DOI: 10.1055/s-2003-39985

Original Paper

Schizophrenic Patients’ Subjective Reasons for Compliance and Noncompliance with Neuroleptic Treatment

W. Löffler¹ , R. Kilian¹ , M. Toumi² , M. C. Angermeyer¹

¹Universtity of Leipzig, Department of Psychiatry, Leipzig, Germany
²H. Lundbeck A/S, Department of Pharma Economics, Valby-Copenhagen, Denmark

The base study was funded by grants from the German Federal Ministry of Education and Research in the framework of the research association public health Saxony (grant no. 01EG9732/7). The second part of the study was funded by H. Lundbeck A/S.

Abstract

Although several factors influencing schizophrenic patients’ compliance with neuroleptic treatment have been investigated, the subjective reasons that patients are willing or reluctant to take medication have rarely been examined. In a follow-up study of a sample of schizophrenic patients currently undergoing psychiatric treatment in the city of Leipzig, 307 patients were asked about their subjective reasons for medication compliance or noncompliance by administering the Rating of Medication Influences (ROMI) Scale. The perceived benefit from medication proved to be the main reason for patients’ compliance with neuroleptic treatment. Respectively, patient-reported noncompliance was mainly explained by negative side effects of medication. However, there were no statistically significant differences in responses between the patients receiving conventional versus second-generation antipsychotics. A positive relationship with the therapist and a positive attitude of significant others toward neuroleptic treatment contributed to patients’ medication compliance. Reasons for noncompliance with neuroleptic treatment were lack of acceptance of the necessity of pharmacological treatment and lack of insight into the disease. The results emphasize the importance of psychoeducation in enhancing patient compliance with neuroleptic treatment.

Volltext

Referenzen

References

1 Agarwal M R, Sharma V K, Kishore Kumar K V, Lowe D. Noncompliance with treatment in patients suffering from schizophrenia: A study to evaluate possible contributing factors. International Journal of Social Psychiatry. 1998; 44(2) 92-106
2 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM IIIR) 3d ed. Washington DC; APA 1994
3 Angermeyer M C, Löffler W, Müller P, Schulze B, Priebe S. Patients’ and relatives’ assessment of clozapine treatment. Psychol Med. 2001; 31 509-517
4 Angermeyer M C, Matschinger H. Neuroleptika und Lebensqualität. Psychiatr Prax. 2000; 27 64-68
5 Angermeyer M C, Matschinger H. Public attitude towards psychiatric treatment. Acta Psychiatr Scand. 1996; 94 326-336
6 Awad A G. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin. 1993; 19 609-618
7 Awad A G, Hogan T P, Voruganti L NP, Heslegraves R J. Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life. International Clinical Pharmacology. 1995; 10 123-132
8 Barnas C, Hummer M, Fleischhacker W W. Compliance Probleme bei der Behandlung schizophrener Patienten. Wiener Medizinische Wochenschrift. 1998; 11 281-283
9 Benkert O, Kepplinger H M, Sobota K. Psychopharmaka im Widerstreit. Berlin; Springer 1995
10 Bollen K A, Lennox R. Conventional wisdom on measurement: A structural equation perspective. Psychol Bull. 1991; 110(2) 305-314
11 Buchanan A. Treatment complicane in schizophrenia. Advances in Psychiatric Treatment. 1998; 4 227-234
12 Cabeza I G, Amador M S, Lopez C A, de Chavez M G. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res. 2000; 41 349-355
13 Chacos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: Areview and meta-analysis of randomized trials. American Journal of Psychiatry. 2001; 158 518-526
14 Chisholm D, Knapp M RJ, Knudson H C, Amaddeo F, Gaite L, vanWijngaarden B. Client Sociodemographic and Service Receipt Inventory - European Version. Br J Psychiatry. 2000; 17 (suppl. 39) 28-33
15 Day J C, Kinderman P, Bentall R. A comparison of patients’ and prescribers’ beliefs about neuroleptic side effects: prevalence, distress and causation. Acta Psychiatr Scand. 1998; 97 93-97
16 Dolder C R, Lacro J P, Dunn L B, Jeste D V. Antipsychotic medication adherence: Is there a difference between typical and atypical agents?. American Journal of Psychiatry. 2002; 159 103-108
17 Fayers P M, Hand D J. Factor analysis, causal indicators and quality of life. Qual Life Res. 1997; 6(2) 39-150
18 Fenton W S, Blyler C R, Heinssen R K. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull. 1997; 23(4) 637-651
19 Fleiss J L. Statistical methods for rates and proportions. New York; John Wiley & Sons 1981
20 Garcia Cabeza I, Sanz Amador M, Arango Lopez C, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenia patients: clinical implications and related factors. Schizophr Res. 2000; 41 349-355
21 Glick I D, Berg P H. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. International Clinical Psychopharmacology. 2002; 17 65-68
22 Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker W W. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. Journal of Clinical Psychiatry. 2002; 63 49-53
23 Hogan T P, Awad A G, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine. 1983; 13 177-183
24 Hornung W P, Feldmann R, Schonauer K, Schafer A, Monking H S, Klingberg S. et al . Psychoedukativ-psychotherapeutische Behandlung von schizophrenen Patienten und ihren Bezugspersonen. II. Ergänzende Befunde der 2-Jahres-Katamnese. Nervenarzt. 1999; 70(5) 444-449
25 Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand. 1999; 100(3) 67-175
26 Kampman O, Lethinen K, Lassila V, Leinonen E, Poutanen O, Koivisto A -M. Attitudes toward neuroleptic treatment: Realiability and validity of the Attitudes towards Neuroleptics Treatment (ANT) questionaire. Schizophr Res. 2000; 45 223-234
27 Kilian R, Lindenbach I, Angermeyer M C. ”(...) manchmal zweifle ich an mir, wenn es mir nicht gut geht” - Die Wirkung eines ambulanten psychoedukativen Gruppenprogramms aus der subjektiven Perspektive von Patienten mit schizophrenen Erkrankungen. Psychiatr Prax. 2001; 28(4) 57-206
28 Kilian R, Roick C, Bernert S, Morry C, Matschinger H, Becker T. et al . Die europäische Standardisierung und die deutschsprachige Adaptation von Instrumenten zur Erfassung der Ergebnisse und der Kosten von Versorgungsleistungen für Menschen mit schweren psychischen Erkrankungen. Gesundheitswesen. 2001; 63 (Sonderheft 1) 27-31
29 Lilly. Are people with schizophrenia getting the best treatment?. Lilly 2000
30 Linden M, Godemann F, Gaebel W, Köpke W, Müller P, Müller-Spahn F. et al . A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. Schizophrenia Bulletin. 2001; 27(4) 585-596
31 Lindström E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics. 2000; 18(2) 05-124
32 McCallum R C, Brown M W. The use of causal indicators in covariance structure models: Some practical issues. Psychol Bull. 1993; 114(3) 533-541
33 Moore A, Sellwood W, Stirling J. Compliance and psychological reactance in schizophrenia. British Journal of Clinical Psychology. 2000; 39 287-295
34 Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995; 10 Suppl 3 33-138
35 National Institute of Mental Health. 12 - CGI. Clinical global impressions. In: Guy W, Bonato RR, editors Manual for the ECDEU assessment battery. 2. rev. ed Maryland; Chevy Chase 1970 : 12-1-12-6
36 Oehl M, Hummer M, Fleischhacker W W. Compliance with antipsychotic treatment. Acta Psychiatr Scand. 2000; 102 83-86
37 Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Henderson T J. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry. 2000; 61 382-386
38 Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Comprehensive Psychiatry. 2000; 41 446-449
39 Ruscher S M, de Wit R, Mazmanian D. Psychiatric patients’ attitudes about medication and factors affecting noncompliance. Psychiatric Services. 1997; 48 82-85
40 Sellwood W, Tarrier N. Demographic factors associated with extreme noncompliance in schizophrenia. Social Psychiatry and Psychiatric Epidemiology. 1994; 29 172-177
41 Taylor D, Shapland L, Laverick G ., Bond J, Munro J. Clozapine - a survey of patient perception. Psychiatr Bull. 2000; 24 450-452
42 Tunnicliffe S, Harrison G, Standen P J. Factors affecting compliance with depot injection treatment in the community. Social Psychiatry and Psychiatric Epidemiology. 1992; 27 230-233
43 Valenstein M, Copeland L A, Owen R, Blow F C, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. Journal of Clinical Psychiatry. 2001; 62 545-551
44 Van Putten T, May P R. Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point. Arch Gen Psychiatr. 1978; 35 477-480
45 Ventura J, Green M F, Shaner A, Lieberman R .P. Training and quality assurance with the brief psychiatric rating scale: ”The Drift Busters”. Intern Meth Psychiatr Res. 1993; 3 221-244
46 Wahlbeck K, Tuunainen A, Ahokas A. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology. 2001; 155 230-233
47 Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz L M. et al . Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994; 20(2) 297-310
48 Wolfson P .W., Paton C. Clozapine audit: What do patients and relatives think?. J Ment Hlth. 1996; 5(3) 267-273

Dr. Reinhold Kilian

Department of Psychiatry

University of Leipzig

Johannisallee 20

D-04317 Leipzig

Telefon: 0341/ 97 24 532

Fax: 0341/ 97 24 539

eMail: kilr@medizin.uni-leipzig.de